Oxford BioMedica plc (LON:OXB) insider Martin Diggle bought 320,000 shares of the business’s stock in a transaction on Friday, September 1st. The stock was purchased at an average price of GBX 9 ($0.12) per share, with a total value of £28,800 ($37,194.89).

Martin Diggle also recently made the following trade(s):

  • On Thursday, August 31st, Martin Diggle sold 2,377,600 shares of Oxford BioMedica plc stock. The stock was sold at an average price of GBX 10 ($0.13), for a total value of £237,760 ($307,064.45).
  • On Thursday, July 13th, Martin Diggle acquired 660,000 shares of Oxford BioMedica plc stock. The shares were bought at an average price of GBX 9 ($0.12) per share, with a total value of £59,400 ($76,714.45).

Shares of Oxford BioMedica plc (OXB) opened at 8.97 on Thursday. The firm’s market cap is GBX 277.02 million. The stock’s 50 day moving average price is GBX 8.91 and its 200-day moving average price is GBX 6.39. Oxford BioMedica plc has a 12 month low of GBX 2.98 and a 12 month high of GBX 11.25.

COPYRIGHT VIOLATION NOTICE: “Martin Diggle Buys 320,000 Shares of Oxford BioMedica plc (OXB) Stock” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/07/martin-diggle-buys-320000-shares-of-oxford-biomedica-plc-oxb-stock.html.

OXB has been the subject of a number of recent research reports. Jefferies Group LLC reiterated a “buy” rating and set a GBX 13 ($0.17) price objective on shares of Oxford BioMedica plc in a research report on Thursday, July 13th. N+1 Singer reiterated a “hold” rating and set a GBX 7.80 ($0.10) price objective on shares of Oxford BioMedica plc in a research report on Thursday, July 6th. Finally, Shore Capital reiterated a “not rated” rating on shares of Oxford BioMedica plc in a research report on Thursday, July 13th.

Oxford BioMedica plc Company Profile

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.

Insider Buying and Selling by Quarter for Oxford BioMedica plc (LON:OXB)

Receive News & Stock Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related stocks with our FREE daily email newsletter.